Aripiprazole (Aripicon (10 mg)) is an atypical antipsychotic and antidepressant, prescribed for schizophrenia and depression. It regulates abnormal conditions like disturbed or unusual thinking, loss ...

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...

Long-term maintenance treatment with an antipsychotic is often required to prevent relapse and mitigate functional deterioration in patients with schizophrenia. This 52-week, open-label study included ...

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...

Aripiprazole is less effective in treating schizophrenia than olanzapine (Zyprexa), but has fewer metabolic and sedative adverse effects. There is no difference in effectiveness between aripiprazole ...

TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) ...

November 24, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for the oral formulation of aripiprazole (Abilify tablets, orally disintegrating tablets, and oral ...

The manufacturer presented direct clinical-effectiveness evidence from 2 randomised controlled trials comparing aripiprazole with placebo and performed a meta-analysis of these trials. The ...

The panelists examined aripiprazole's pivotal trial design, which used an antidepressant lead-in phase followed by randomization to placebo or active drug among non-responders, with Thase detailing ...

There are several takeaways from the trial. Aripiprazole and bupropion augmentation produce similar modest improvements, and both are a reasonable option. Although injurious falls appear to be more ...

TOKYO and PRINCETON, N.J., Nov. 6 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY - News) announced today that the U.S. Food and Drug Administration (FDA) approved the ...

FARMINGTON, Conn., April 3 -- The atypical antipsychotic aripiprazole (Abilify), modified the behavioral and physiological effects of alcohol, according to a preliminary study. Aripiprazole ...